SoftBank-backed Vir Biotechnology’s shares tumble in market debut

Shares of SoftBank-backed Vir Biotechnology Inc fell as much as 28% in one of the worst market debuts in recent months, adding to the gloom in the IPO market after WeWork’s failed attempt to list its stock.